Chemoradiotherapy combined with ICIs in the treatment of high PD-L1 expression-sensitive patients with non-small cell lung cancer

The exploration of the efficacy of chemoradiotherapy combined with camrelizumab (ICIs) in the therapy of non-small cell lung carcinoma (NSCLC) in high PD-L1 expression-sensitive populations. 78 patients with advanced NSCLC were divided into a combination group treated with ICIs (camrelizumab) based on the control group and a control group treated with concurrent chemoradiotherapy. Objective response rate (ORR) and the incidence of toxic side effects were observed. The ORR of the combination group was increased in comparison to that of the control one. After therapy, the CD4 + and CD3 + levels in the combination one and the control one were clearly increased compared to those at pre-therapy, and the CD8 + levels were clearly reduced in comparison to those at pre-therapy. And the CD4 + and CD3 + levels in the combination one after therapy were lower. The CD8 + level in the combination one was decreased. After therapy, the serum CEA, CYFRA21-1, and CA125 levels in the combination one and the control one were clearly less than those at pre-therapy. And after treatment, the serum CEA, CYFRA21-1, and CA125 levels in the combination one were clearly less. After treatment, the serum FAS and TuM2-PK levels in the combination one and the control one were clearly decreased compared to those at post-therapy. And after therapy, the serum FAS and TuM2-PK levels in the combination one were reduced. There was no significant difference in the overall survival rate of the combination group compared with the control group 12 months after enrollment ( P > 0.05). ICIs combined with chemoradiotherapy can significantly control disease progression, improve their immune function, and reduce serum tumor marker levels without significantly increasing the toxic with toxicity of patients.